Low serum magnesium level predicts major adverse cardiac events after coronary artery bypass graft surgery - 28/08/11
, Barbara Phillips-Bute, PhD a, Charles B McCants, BS c, Mihai V Podgoreanu, MD a, Peter K Smith, MD b, Joseph P Mathew, MD a, Mark F Newman, MD aAbstract |
Background |
Despite improved myocardial protection strategies and enhanced surgical techniques, mortality after coronary artery bypass graft surgery (CABG) remains essentially unchanged. This may be because of the increasing age of patients who undergo primary CABG. Magnesium is an important regulator of vascular tone, reperfusion injury, and thrombosis. Therefore, we decided to investigate the relationship between serum magnesium levels and major adverse cardiac events (MACE) after CABG.
Methods |
A total of 957 patients undergoing primary CABG were prospectively recruited into the Duke Cardiovascular database and had daily serum magnesium levels measured. Low magnesium was defined as <1.8 mmol/L−1 at any point during the first 8 days after surgery. Adverse events were defined as Q-wave infarction or death measured 1 year after surgery. A Kaplan-Meier survival analysis was performed, followed by a Cox proportional hazards model, to account for other known predictors of adverse events.
Results |
In the low magnesium group, 12.3% of patients had adverse events, compared with 9.2% of patients in the normal magnesium group. A serum magnesium level <1.8 mmol/L−1 decreased the event-free survival rate (2-fold increased risk of death or myocardial infarction at 1 year; hazard ratio 2.0, 95% CI 1.19–3.37).
Conclusions |
We demonstrated a robust relationship between low serum magnesium levels after CABG and a 2-fold increased incidence of Q-wave infarction and all-cause mortality rate as long as 1 year after surgery. This relationship is independent of known preoperative and intraoperative predictors of adverse outcomes. This study provides a rationale for a randomized controlled trial of magnesium therapy during CABG.
Le texte complet de cet article est disponible en PDF.Plan
 | Supported by the Department of Anesthesiology and Critical Care at Duke University Medical Center and the Duke Clinical Research Institute, and by a grant from the National Institutes of Health (M01-RR-30). Guest Editor for this manuscript was Hartzell V. Schaff, MD, The Mayo Clinic, Rochester, Minn. |
Vol 145 - N° 6
P. 1108-1113 - juin 2003 Retour au numéro
Article précédent
- Contribution of peak respiratory exchange ratio to peak VO2 prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity
- Alessandro Mezzani, Ugo Corrà, Enzo Bosimini, Andrea Giordano, Pantaleo Giannuzzi
- Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial
- Sanjay Rajagopalan, Emile Mohler, Robert J Lederman, Jorge Saucedo, Farrell O Mendelsohn, Jeffrey Olin, John Blebea, Corey Goldman, Jeffrey D Trachtenberg, Milton Pressler, Henrik Rasmussen, Brian H Annex, Alan T Hirsch
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?